Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VacciPrema: DTP-Pertussis-Hib Vaccination Schemes in Very Preterm Infants
NCT02179996Phase 4Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Jan 2014
- Primary completion
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Infanrix Hib in diphtheria, Tetanus, pertussis and 1 more, sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Haemophilus influenzae type b antibody dosage at 5 months. Status: unknown.
02
Drugs
Infanrix Hib
03
Conditions
diphtheriaTetanuspertussisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT02179996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179996.